DFTX — Definium Therapeutics, Inc.
—
Nasdaq ·
Materials ·
Chemicals ·
CIK 1813814 ·
Last close
$34.18
Market Cap
$4.59B
52W High
$49.70
52W Low
$10.47
ADV30
2,267,895
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -75,077,000 | -158,986,000 | 1,112,899,000 | 655,267,000 | 194,220,000 |
| Mar 2026 | 0 | — | -59,220,000 | -77,098,000 | 401,293,000 | 262,518,000 | 122,444,000 |
| Dec 2025 | 0 | — | -47,578,000 | -50,436,000 | 440,100,000 | 257,837,000 | 107,773,000 |
| Sep 2025 | 0 | — | -45,669,000 | -67,265,000 | 236,916,000 | 19,959,000 | 106,320,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-144,772,000
Investing CF
$52,852,000
Financing CF
$271,576,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.34
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-659,770,000
Inventory
—
Receivables
—
ST Investments
$110,904,000
EBIT TTM
$-231,418,000
Pretax Income TTM
$-237,543,000
Interest Exp TTM
$6,125,000
Analysts
16
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -166,309,000 | -183,793,000 | 440,100,000 | 107,773,000 | 332,327,000 | -131,560,000 |
| Dec 2024 | 0 | -103,916,000 | -108,679,000 | 302,151,000 | 60,703,000 | 241,448,000 | -79,129,000 |
| Dec 2023 | 0 | -93,866,000 | -95,732,000 | 124,541,000 | 46,407,000 | 78,134,000 | -64,365,000 |
| Dec 2022 | 0 | -66,331,000 | -56,796,000 | 169,993,000 | 19,076,000 | 150,917,000 | -50,139,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-237,543,000
OpCashFlow TTM
—
Assets (Latest)
$401,293,000
Forward EPS
$-1.88
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRM | Perimeter Solutions, Inc. | $4.53B | $27.70 | — |
| CSW | CSW INDUSTRIALS, INC. | $4.67B | $286.62 | — |
| MEOH | METHANEX CORP | $4.80B | $62.04 | — |
| CE | Celanese Corp | $4.92B | $44.81 | — |
| BCPC | BALCHEM CORP | $5.38B | $168.63 | — |
News headlines (Yahoo Finance, 1h cache)
Definium Therapeutics Announces New Employee Inducement Grants
2026-09-28 20:01 · Yahoo
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression
2026-09-24 06:02 · Yahoo
Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching
2026-09-20 16:28 · Yahoo
Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study
2026-09-19 23:02 · Yahoo
Definium Therapeutics (DFTX) Stock May Trade At A Premium Despite Phase 3 DT120 Results
2026-09-15 13:12 · Yahoo
Definium tees up regulatory submission for psychedelic on Phase III hat trick
2026-09-15 11:04 · Yahoo
Why Definium Therapeutics (DFTX) Is Up 5.7% After Second Positive Phase 3 DT120 Anxiety Trial Result
2026-09-15 09:12 · Yahoo
Definium Therapeutics (DFTX) After Its Phase 3 Win Still Looks Undervalued
2026-09-15 08:11 · Yahoo
The Psychedelics News That Sent Definium, Already Up 190% This Year, Soaring
2026-09-14 20:10 · Yahoo
Psychedelics Are Wall Street’s Next Trip. Why This Biotech Stock Is Already Up 200%.
2026-09-14 19:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.